Recent meta‐analyses suggest that anti‐VEGF may better reduce myopia and delay recurrence in ROP (Ortiz‐Seller et al., 2024; Xu et al., 2023), but evidence on systemic side effects and structural outcomes, such as retinal detachment, remains inconclusive (Chen et al., 2023; Popovic et al., 2021; Sankar et al., 2018; Taher et al., 2022). Here, VEGFA is linked to retinopathy of prematurity.